ArticleFuture oncology (London, England)2022

Solid cancer patients achieve adequate immunogenicity and low rate of severe adverse events after SARS-CoV-2 vaccination.

Urska Janzic et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.